Indeed, our proteomic approach has identified several receptors interacting with R-RAS2 and known to impact BC development or malignant behavior, including receptor tyrosine kinase Epha2, β-catenin 1, α-catenin, Ptk7, and CD44. Here, CD44 is linked to breast cancer.